medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2013-9-70-75medsovet-1106Research ArticleОРГАНОПРОТЕКЦИЯ ПРИ ССПОбзор сердечно-сосудистых рисков у пациентов с сахарным диабетом 2-го типа на фоне приема глибенкламидаАn overview of cardiovascular risks in patients with type 2 diabetes receiving glibenclamideЧерниковаН. А.ChernikovaN. A.noemail@neicon.ruЕрмаковаЕ. А.ErmakovaE. A.noemail@neicon.ruРМАПОРоссияthe Russian Medical Academy of Postgraduate EducationRussian Federation201330122013097075Copyright © Черникова Н.А., Ермакова Е.А., 20132013Черникова Н.А., Ермакова Е.А.Chernikova N.A., Ermakova E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1106

Сахарный диабет 2-го типа — это хроническое, прогрессирующее заболевание, которое приводит к развитию специфических сосудистых осложнений: микроангиопатии и макроангиопатии. Данные осложнения являются причиной повышенной сердечно-сосудистой летальности больных с сахарным диабетом 2-го типа, в 4—5 раз превышающей этот показатель в общей популяции.

Diabetes mellitus type 2 is a chronic progressive disease which leads to specific vascular complications - microangiopathy and macroangiopathy. These complications are the reason of increased cardiovascular mortality, which is 4-5 times higher in patients with type 2 diabetes mellitus than in the general population.

diabetes mellitusvascular complicationsantihyperglycemic drugsglibenclamideсахарный диабетсосудистые осложнениясахароснижающие препаратыглибенкламидReferencesUK Prospective Diabetes Study (UCPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compered with conventional treatment and risk of complications in patients with 1 diabetes (UKPDS) // Lancet. 1998. №352. Р. 837–853.UK Prospective Diabetes Study (UCPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compered with conventional treatment and risk of complications in patients with 1 diabetes (UKPDS) // Lancet. 1998. №352. Р. 837–853.Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. 2008. №358. Р. 2560–2572.Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. 2008. №358. Р. 2560–2572.Kahn S.E., Zinman B., Lachin J.M. et al. (A Diabetes Outcome Progression Trial [ADOPT] Study Group). Rosiglitazone-associated fractures in type 2 diabetes:an analysis from A Diabetes Outcome Progression Trial (ADOPT) // Diabetes Care. 2008. №31. P. 845–851.Kahn S.E., Zinman B., Lachin J.M. et al. (A Diabetes Outcome Progression Trial [ADOPT] Study Group). Rosiglitazone-associated fractures in type 2 diabetes:an analysis from A Diabetes Outcome Progression Trial (ADOPT) // Diabetes Care. 2008. №31. P. 845–851.Pantalone K.M., Kattan M.W., Yu C., Wells B.J., Arrigain S., Jain A., Atreja A., Zimmerman R.S. The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy. A retrospective analysis // Diabetes Care. 2010. №33. Р. 1224–1229.Pantalone K.M., Kattan M.W., Yu C., Wells B.J., Arrigain S., Jain A., Atreja A., Zimmerman R.S. The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy. A retrospective analysis // Diabetes Care. 2010. №33. Р. 1224–1229.Schramm T.K., Gislason G.H., Vaag A. et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study // Eur. Heart J. 2011. №32. Р. 1900–1908.Schramm T.K., Gislason G.H., Vaag A. et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study // Eur. Heart J. 2011. №32. Р. 1900–1908.Kristiansen S.B., Lofgren B., Nielsen J.M. et al. Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes. Diabetologia. 2011. №54. Р. 451–458.Kristiansen S.B., Lofgren B., Nielsen J.M. et al. Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes. Diabetologia. 2011. №54. Р. 451–458.Loubani M., Fowler A., Standen N.B., Galinanes M. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium // Eur. J. Pharmacol. 2005. №515. Р. 142–149.Loubani M., Fowler A., Standen N.B., Galinanes M. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium // Eur. J. Pharmacol. 2005. №515. Р. 142–149.Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). Meier J.J., Deifuss S., Klamann A., Launhardt V., Schmiegel W.H., Nauck M.A. // Diabetes Care. 2005. Oct. №28(10). Р. 2551–2553. No abstract available.Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). Meier J.J., Deifuss S., Klamann A., Launhardt V., Schmiegel W.H., Nauck M.A. // Diabetes Care. 2005. Oct. №28(10). Р. 2551–2553. No abstract available.Lomuscio A. et al. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction // Coronary Artery Disease. 1994. Vol. 5. P. 767–771.Lomuscio A. et al. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction // Coronary Artery Disease. 1994. Vol. 5. P. 767–771.Davis T.M. et al. A rrhythmias and Mortality After Myocardial Infarction in Diabetic Patients // Diabetes Care. 1998. Vol. 21. №4. P. 637–640.Davis T.M. et al. A rrhythmias and Mortality After Myocardial Infarction in Diabetic Patients // Diabetes Care. 1998. Vol. 21. №4. P. 637–640.Gangji A.S., Cukierman T., Gerstain H.C., Goldsmith C.H., Clase C.M. A systematic review and meta-analysis of hypoglycemia and cardiovascular events. A comparison of glyburide with other secretagogues and with insulin // Diabetes Care. 2007. №30. P. 389–394.Gangji A.S., Cukierman T., Gerstain H.C., Goldsmith C.H., Clase C.M. A systematic review and meta-analysis of hypoglycemia and cardiovascular events. A comparison of glyburide with other secretagogues and with insulin // Diabetes Care. 2007. №30. P. 389–394.Holstein A., Plaschke A., Egberts E.H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide // Diabetes Metab. Res. Rev. 2001. Vol. 17. №6. P. 467–473.Holstein A., Plaschke A., Egberts E.H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide // Diabetes Metab. Res. Rev. 2001. Vol. 17. №6. P. 467–473.Chen M., Simard J.M. Cell swelling and a nonselective cation channel regulated by internal Ca2 and ATP in native reactive astrocytes from adult rat brain // J. Neurosci. 2001. Vol. 21. P. 6512–6521.Chen M., Simard J.M. Cell swelling and a nonselective cation channel regulated by internal Ca2 and ATP in native reactive astrocytes from adult rat brain // J. Neurosci. 2001. Vol. 21. P. 6512–6521.Chen M., Dong Y., Simard J.M. Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain // J. Neurosci. 2003. Vol. 23. P. 8568–8577.Chen M., Dong Y., Simard J.M. Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain // J. Neurosci. 2003. Vol. 23. P. 8568–8577.Simard J.M., Chen M., Tarasov K.V. et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke // Nat. Med. 2006. Vol. 12. P. 433–440.Simard J.M., Chen M., Tarasov K.V. et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke // Nat. Med. 2006. Vol. 12. P. 433–440.Chen M., Simard J.M. Cell swelling and a nonselective cation channel regulated by internal Ca2 and ATP in native reactive astrocytes from adult rat brain // J. Neurosci. 2001. Vol. 21. P. 6512–6521.Chen M., Simard J.M. Cell swelling and a nonselective cation channel regulated by internal Ca2 and ATP in native reactive astrocytes from adult rat brain // J. Neurosci. 2001. Vol. 21. P. 6512–6521.Chen M., Simard J.M. Cell swelling and a nonselective cation channel regulated by internal Ca2 and ATP in native reactive astrocytes from adult rat brain // J. Neurosci. 2001. Vol. 21. P. 6512–6521.Chen M., Simard J.M. Cell swelling and a nonselective cation channel regulated by internal Ca2 and ATP in native reactive astrocytes from adult rat brain // J. Neurosci. 2001. Vol. 21. P. 6512–6521.Kunte H. et al. Sulfonylureas Improve outcomes in patients with Type 2 diabetes and acute ischemic stroke // Stroke. 2007. Vol. 38. P. 2526–2530.Kunte H. et al. Sulfonylureas Improve outcomes in patients with Type 2 diabetes and acute ischemic stroke // Stroke. 2007. Vol. 38. P. 2526–2530.Kunte H., Busch M.A., Trostdorf K., Vollnberg B., Harms L., Mehta R.I., Castellani R.J., Mandava P., Kent T.A., Simard J.M. Hemorrhagic ransformation of ischemic stroke in diabetics on sulfonylureas // Ann. Neurol. 2012. Nov. №72(5). Р. 799–806. doi: 10.1002/ana.23680.Kunte H., Busch M.A., Trostdorf K., Vollnberg B., Harms L., Mehta R.I., Castellani R.J., Mandava P., Kent T.A., Simard J.M. Hemorrhagic ransformation of ischemic stroke in diabetics on sulfonylureas // Ann. Neurol. 2012. Nov. №72(5). Р. 799–806. doi: 10.1002/ana.23680.Kahn S.E., Haffner S.M., Heise M.A. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy // N. Engl. J. Med. 2006. №355(23). Р. 2427–2443.Kahn S.E., Haffner S.M., Heise M.A. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy // N. Engl. J. Med. 2006. №355(23). Р. 2427–2443.Davidson J.A., Scheen A.J., Howlett H.C.Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus // Drug Saf. 2004. №27(15). Р. 1205–1216.Davidson J.A., Scheen A.J., Howlett H.C.Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus // Drug Saf. 2004. №27(15). Р. 1205–1216.Gangi A.S., Cukierman T., Gestain H.C., Goldsmith C.H. Clase C.M. A systematic review and meta-analisis of hypoglycaemia and cardiovascular events. A comprasion of gliburide with other secretagogues and with insulin // Diabetes Care. 2007. №30. P. 389–394.Gangi A.S., Cukierman T., Gestain H.C., Goldsmith C.H. Clase C.M. A systematic review and meta-analisis of hypoglycaemia and cardiovascular events. A comprasion of gliburide with other secretagogues and with insulin // Diabetes Care. 2007. №30. P. 389–394.Charca A.R., Tan G.H., Aponovitch A. et.al Saxagliptin added to a submaximal dose of sulfonylurea improves glycaemic control compared with uptitration of sulfonylurea in patients with type 2 diabetes: a randomized controlled trial // Int. J. Clin. Pract. 2009. №63. P.1395–1406.Charca A.R., Tan G.H., Aponovitch A. et.al Saxagliptin added to a submaximal dose of sulfonylurea improves glycaemic control compared with uptitration of sulfonylurea in patients with type 2 diabetes: a randomized controlled trial // Int. J. Clin. Pract. 2009. №63. P.1395–1406.Serra D., He Y.L., Bullock J., Riviere G.J., Balez S., Schwartz S., Wang Y. Evaluation of pharmacokinetic and pharmakodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes // Int. J. Clin. Pharmacol Ther. 2008. №46. P. 349–364.Serra D., He Y.L., Bullock J., Riviere G.J., Balez S., Schwartz S., Wang Y. Evaluation of pharmacokinetic and pharmakodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes // Int. J. Clin. Pharmacol Ther. 2008. №46. P. 349–364.

The authors declare that there are no conflicts of interest present.